Trials / Completed
CompletedNCT04318080
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a Phase 2 trial evaluating the effectiveness and safety of tislelizumab in participants with relapsed or hard-to-treat classical Hodgkin lymphoma (cHL). Participants were grouped by prior treatments. The main outcome was to assess overall response rate (ORR) across both cohorts. Participants continued receiving the study treatment until their disease got worse, side effects became too severe, or they chose to stop for other reasons.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | 200 milligrams (mg) intravenously every 3 weeks (Q3W) |
Timeline
- Start date
- 2020-08-20
- Primary completion
- 2022-12-12
- Completion
- 2024-08-29
- First posted
- 2020-03-23
- Last updated
- 2025-09-24
- Results posted
- 2025-09-24
Locations
4 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04318080. Inclusion in this directory is not an endorsement.